# Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

> **NCT00910520** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 548 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **BIOLOGICAL:** onabotulinumtoxinA
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT00910520
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 548 (ACTUAL)
- **Last updated:** 2013-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910520, "Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00910520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*